1. Introduction {#s0005}
===============

*Aspergillus fumigatus* is a ubiquitous saprophytic fungus. Its ecological niche is soil, where it plays a key role in carbon and nitrogen recycling by degradation of organic biomass ([@b0270], [@b0345]). Various characteristics enable *A. fumigatus* to survive in this harsh environment, including rapid germination, growth at higher temperatures and nutritional metabolic flexibility ([@b0260]). This versatility enables *A. fumigatus* to be a successful pathogen in human, animal and plant populations ([@b0035], [@b0120]).

In humans, *A. fumigatus* is the causative agent of aspergillosis, which ranges from allergic syndromes to life-threatening invasive aspergillosis ([@b0215], [@b0365]). Azole antifungal agents hold great importance in the treatment of aspergillosis, as they are the only orally available anti-*Aspergillus* agents ([@b0280], [@b0290], [@b0365]). The primary target of azoles is cytochrome P450 14α-sterol demethylase (Cyp51A), which catalyses the demethylation of ergosterol precursors in the ergosterol biosynthetic pathway ([@b0055], [@b0150], [@b0315]). Azoles competitively inhibit Cyp51A by binding to the haem active site ([@b0160], [@b0375]).

In order to survive and thrive in-host, *A. fumigatus* must adapt to specific niche environments ([@b0360]). Genetic adaptation can be defined as the acquisition of heritable modifications, via either spontaneous mutation or recombination, which enable survival and reproduction in the environment ([@b0310]). Examples of adaptation include adaptation to enable persistent infection and azole resistance development ([@b0115], [@b0170], [@b0195], [@b0355], [@b0360]). The in-host acquisition of resistance has previously been described within aspergillomas in chronic pulmonary aspergillosis ([@b0185]).

Since the first report of itraconazole resistance in *A. fumigatus* in 1997 ([@b0100]), azole resistance is increasingly reported globally. A range of molecular mechanisms conferring azole resistance have been described. Specific non-synonymous point mutations in *cyp51A* have been shown to confer azole resistance by altering the ligand entry channel structure; examples include G54, P216, G138 and M220 ([@b0010], [@b0140], [@b0230], [@b0240], [@b0235], [@b0330]). A tandem repeat of 34 bp in the promoter region of *cyp51A* has also been shown to confer itraconazole resistance by increasing *cyp51A* gene expression in combination with an L98H mutation within *cyp51A* ([@b0245], [@b0335]). In contrast to *cyp51A*-mediated resistance mechanisms, relatively few non *cyp51A*-mediated mechanisms have been described. One example is a P88L substitution in the CCAAT-binding transcription factor complex subunit HapE, which has been shown to confer itraconazole resistance by enhancing *cyp51A* expression ([@b0080]). Overexpression of efflux transporters AtrF and Cdr1B has been associated with azole resistance ([@b0130], [@b0325]) but further research is required to validate the role of these pumps in azole resistance. Mutation in components of mitochondrial complex I, RamA (farnesyltransferase β-subunit), overexpression of *cyp51B* and deletion of cytochrome b~5~ CybE have also been described to result in azole resistance ([@b0065], [@b0075], [@b0255], [@b0265]).

Cyp51A-mediated resistance mechanisms are not thought to be associated with fitness costs ([@b0210], [@b0355]). In contrast, the HapE itraconazole resistance mechanism is associated with a growth defect ([@b0080]). Interestingly, specific azole resistant isolates are hypothesised to be 'azole addicted' whereby they exhibit enhanced growth in the presence of azole antifungals ([@b0025], [@b0305]).

Studies investigating the dynamics of in-host adaptation and persistent infection are scarce. Here we performed a detailed phenotypic and genotypic analysis of 13 *A. fumigatus* isolates consecutively cultured over a period of 2 years with increasing azole resistance in a chronic granulomatous disease (CGD) patient with chronic and recurrent aspergillosis. Whole genome sequencing was used to assess the genomic dynamics. Phenotypic analysis including growth in liquid and on solid media and conidiation assays were used to investigate physiological adaptation. An invertebrate infection model was used to assess differences in virulence.

2. Materials and methods {#s0010}
========================

2.1. Origin and characterisation of fungal isolates {#s0015}
---------------------------------------------------

The 13 isolates used in this study were cultured from a 36-year-old male diagnosed with X-linked chronic granulomatous disease with severe chronic obstructive pulmonary disease (Gold IV) and allergic bronchopulmonary aspergillosis ([@b0360]). The patient suffered from 3 episodes of invasive aspergillosis and developed an aspergilloma, which could not be surgically removed due to his poor respiratory condition. The patient was treated prophylactically with interferon-gamma, trimethoprim-sulphamethoxazole and itraconazole. Between June and December 2011, the patient was treated with itraconazole followed by combination therapy consisting of voriconazole and an echinocandin (caspofungin, anidulafungin). Isolate V130-15 was collected on 22/11/11 and isolates V130-14, V130-18 and V130-54 were collected on 25/11/11. Between December 2011 and January 2013 the patient was treated consecutively with liposomal amphotericin B, itraconazole, anidulafungin in combination with voriconazole. Between August and December 2013, the patient was treated with posaconazole monotherapy, followed by combination therapy with micafungin. Despite these efforts, eradication of the fungus was not achieved. Isolates V157-39, V157-40, V157-47, V157-48 and V157-62 were collected on 9/12/13. Isolates V157-59, V157-60 and V157-61 were collected on 12/12/13; and isolate V157-80 was collected on 19/12/13. Unfortunately the patient died from his infection.

The 13 *A. fumigatus* isolates were cultured and morphologically identified as *A. fumigatus* at Radboud University Medical Centre ([@b0360]). *In vitro* susceptibility testing of the isolates was performed according to the EUCAST broth microdilution reference method ([@b0340]). Isolates were tested at a final drug concentration rage of 0.0312--16 mg/L itraconazole (Sigma Aldrich, UK), 0.0312--16 mg/L voriconazole (Pfizer, UK) and 0.0156--8 mg/L posaconazole (Sigma Aldrich, UK). A no growth end point was determined by eye. Short tandem repeat (STR) typing was performed as described previously using microsatellite loci STR*Af* 3A, 3B, 3C, 4A, 4B and 4C ([@b0095]). Repeat numbers at each loci were determined by PCR and subsequent sequencing.

2.2. Conidial suspension preparation {#s0020}
------------------------------------

*A. fumigatus* conidia were spread onto diluted Sabouraud dextrose agar in T75 culture flasks (Greiner Bio-One, Germany) and incubated at 37 °C for 7 d. Diluted Sabouraud dextrose agar was selected to promote sporulation. Conidia were harvested *via* immersion in 30 mL phosphate buffered saline (PBS) (Thermo Fisher Scientific, UK) containing 0.05% Tween-80 (Thermo Fisher Scientific, UK). Conidial suspensions were passed through a sterile 40 µm strainer to remove hyphal fragments, washed twice using PBS and then counted using a Neubauer improved haemocytometer ([@b0285]). For all experiments, suspensions were diluted as required in RPMI (RPMI 1640 + Glutamax, Fisher Scientific, UK).

2.3. Whole genome sequencing {#s0025}
----------------------------

DNA was extracted from either conidia or mycelium. Conidia were suspended in TE buffer (pH 8, 1% SDS, 2% Triton X100, 100 mM NaCl). The suspension was shaken for 30 min at 70 °C. DNA was extracted using phenol/chloroform extraction and purified using the QIAamp DNA Blood Mini kit (Qiagen, Germany). A fragmented genomic DNA library was prepared using a Nextera XT DNA sample preparation kit (Illumina, USA). Subsequent sequencing was conducted in a paired end 2 × 150 bp mode using an Illumina NextSeq 500 machine (Illumina, USA).

2.4. Bioinformatics analysis {#s0030}
----------------------------

Raw reads were quality checked using FastQC (version 0.11.5, Babraham Institute). Reads containing adapter sequences and/or with a Phred score \<30 were removed using Trimmomatic (Galaxy version 0.32.3) ([@b0050], [@b0155]). Reads were mapped to the Af293 reference genome (release 31, EnsemblFungi) using the very sensitive local align preset mode in Bowtie2 ([@b0135]). Mapping quality was assessed using Qualimap ([@b0135], [@b0275]). Single nucleotide polymorphism (SNP) detection was conducted using FreeBayes ([@b0145]). VCFtools vcf-isec was used to assess patterns amongst SNPs and to filter SNPs with a minimum coverage of 5 and a minimum probability of 0.8 ([@b0090]). EnsemblFungi Variant Effect Predictor was used to assess the impact of non-synonymous SNPs ([@b0125]). Both synonymous and non-synonymous SNPs were considered for phylogenetic analysis using the SNPhylo pipeline ([@b0220]), which utilises vcftools ([@b0090]), Phylip (University of Washington, USA) and Muscle ([@b0105]) to generate phylogenetic trees by the maximum likelihood method. Integrated Genomics Viewer and Tablet were utilised for visualisation of sequence data ([@b0060], [@b0250], [@b0350]).

2.5. Growth assays {#s0035}
------------------

### 2.5.1. Liquid medium {#s0040}

Flat-bottomed 96-well plates (Nunc microwell 96F, Thermo Fischer Scientific, UK) were seeded with 1.9 × 10^5^ conidia in RPMI. Selected wells were supplemented with specific concentrations of posaconazole (POS 0.5--1 mg/L), voriconazole (VORI 1--4 mg/L) or 2.5 mM *tert*-Butyl hydroperoxide (*t*BOOH) (Sigma Aldrich, UK). Plates were incubated at 37 °C for 48 h inside a spectrophotometric plate reader (FLUOstar OPTIMA, BMG Labtech, Germany). Optical density at 450 nm was automatically measured every 20 min with 5 s shaking before every reading. Each condition was performed in triplicate wells and repeated twice. Due to the lipophilic properties of itraconazole (ITR), specific concentrations were unable to be determined in liquid media; solid media assays were consequently used for studying the impact of ITR on growth.

### 2.5.2. Solid medium {#s0045}

Sabouraud dextrose agar plates were spot-inoculated with 5 × 10^2^ conidia. Selected plates were supplemented with specific concentrations of either ITR (between 1 and 8 mg/L) or 2.5 mM *t*BOOH. Supplements were added to the medium at ∼50 °C before solidification. Plates were incubated at 37 °C for 96 h, colony diameters were measured every 24 h. Each condition was performed in triplicate.

### 2.5.3. Environmental zinc depletion {#s0050}

*A. fumigatus* conidia were spread onto glucose minimal agar lacking zinc in T75 culture flasks and incubated at 37 °C for 7 d. Conidia were harvested and counted as described. Zinc depletion experiments were performed by spot inoculating 5 × 10^2^ conidia on glucose minimal media in the absence and presence of 1 mM zinc at pH 4.5 and 7.5 ([@b0015]). Plates were incubated at 37 °C for 96 h, colony diameters were measured every 24 h. Each condition was performed in triplicate.

### 2.5.4. Conidiation quantification {#s0055}

T75 culture flasks containing Sabouraud dextrose agar were inoculated with 1 × 10^5^ conidia and incubated at 37 °C for 7 d. Selected flasks were supplemented with 4 mg/L ITR. Conidial suspensions were prepared and counted as described above. Where sterile hyphae were produced, a 1 cm^3^ section of hyphae was excised using a sterile plastic loop, re-plated and incubated at 37 °C for an additional 7 d. Conidial suspensions were subsequently prepared and counted as described. Each condition was performed in duplicate.

2.6. Galleria mellonella virulence assays {#s0060}
-----------------------------------------

Similar sized *G. mellonella* larvae (Livefood Ltd, UK) were selected for use in experiments*.* All larval injections were performed in the last pro-leg using a 0.33 mm Micro-Fine needle (BD, UK). Groups of 10 larvae were infected with 6 × 10^3^ conidia. Control groups of larvae were included in each experiment; 10 unmanipulated larvae and 10 larvae injected with 10 µl PBS. Larvae were incubated at 37 °C for 6 d. Larval death was characterised by lack of movement and melanisation ([@b0165], [@b0295], [@b0320]). Virulence assays were performed in duplicate.

2.7. Statistical analysis {#s0065}
-------------------------

Statistical significance was assessed using a two-tailed Students T-test. Survival curves comparisons were performed using a log-rank Mantel-Cox test. A p value of \<0.05 was considered significant.

3. Results {#s0070}
==========

3.1. Initial characterisation of the A. Fumigatus isolates {#s0075}
----------------------------------------------------------

### 3.1.1. Validation of genetic relatedness {#s0080}

Microsatellite typing was performed in order to verify genetic relatedness between the 13 isolates ([@b0095]). STRAf loci 3A, 3B, 3C, 4A, 4B and 4C were assessed. All isolates showed identical repeat numbers at all loci except for 3C and 4A. Isolates showed 26 repeats at 3A, 9 repeats at 3B, 12 repeats at 4B and 8 repeats at 4C. At locus 3C isolates showed 16 repeats, with the exception of isolates V130-15 and V130-18 which showed 17 repeats. At locus 4A isolates showed 9 repeats, with the exception of isolates V157-39, V157-40 and V157-80 which showed 8 repeats. As repeat numbers at these loci differed by only one single repeat the isolates are considered isogenic.

### 3.1.2. Development of triazole resistance {#s0085}

According to the EUCAST clinical resistance breakpoints, isolates V130-15 and V130-14 were azole susceptible, while isolate V130-54 was itraconazole (ITR) resistant. Furthermore, isolates V130-18, V157-62, V157-59, V157-60 and V157-61 were pan-azole resistant, whereas isolates V157-39, V157-40, V157-47, V157-48 and V157-80 were ITR and posaconazole (POS) resistant ([Table 1](#t0005){ref-type="table"}).Table 1Minimum inhibitory concentrations of the *A. fumigatus* isolates in the series.Isolation dateStrainCyp51A SNPMinimum inhibitory concentration (MIC; mg/L)ItraconazoleVoriconazolePosaconazole22/11/11V130-15110.2525/11/11V130-14110.2525/11/11V130-18**440.5**25/11/11V130-54**\>16**10.12509/12/13V157-39**G54R\>16**1**\>16**09/12/13V157-40**G54V\>16**1**\>16**09/12/13V157-47**P216L\>16**2**\>16**09/12/13V157-48**P216L\>16**2**\>16**09/12/13V157-62**M220R\>168\>16**12/12/13V157-59**M220R\>164\>16**12/12/13V157-60**M220R\>164\>16**12/12/13V157-61**M220R\>164\>16**19/12/13V157-80**P216L\>16**1**\>16**[^1]

### 3.1.3. Differences in colony morphology {#s0090}

Colony morphology differed hugely between isolates. The first 5 isolates (V130-15, V130-14, V130-18, V130-54, V157-39 and V157-40) produced wild-type green colonies whereas subsequent isolates produced predominantly white, sterile hyphae. Remarkably, the final isolate collected (V157-80) produced green[1](#fn1){ref-type="fn"} colonies again ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1Observed colony morphology of the series. Sabouraud dextrose agar plates were spot inoculated with 5 × 10^2^ conidia and incubated at 37 °C for 96 h.

3.2. In depth characterisation of the isolates {#s0095}
----------------------------------------------

### 3.2.1. Whole genome comparisons between isolates {#s0100}

Af293 was used as the reference genome based on assessment of mapping quality and coverage statistics; mean coverage across the series was 65X and mean mapping quality was 40 ([Table A.1](#t0015){ref-type="table"}). SNP-based full genome phylogenetic analysis was performed ([@b0220]). The sequences of various unrelated isolates were included in the phylogenetic analysis; a clinical isolate from Japan (IFM59361-1) ([@b0170]), a clinical isolate from the UK (09-7500806) ([@b0005]), an environmental isolate from the Netherlands (08-19-02-61) ([@b0005]) and a clinical isolate from India (Afu 1042/09) ([@b0005]). [Fig. 2](#f0010){ref-type="fig"}A highlights the genetic closeness of the series, as unrelated isolates showed greater genetic distance and diversity. In agreement with microsatellite typing results, whole genome sequencing verified the isolates to be isogenic ([Fig. 2](#f0010){ref-type="fig"}A). The first strain to be isolated (V130-15) was verified to be the precursor to the series ([Fig. 2](#f0010){ref-type="fig"}B). Later isolates appear to take on independent lineages of microevolution from the precursor isolate.Fig. 2Phylogenetic tree based on whole genome sequences of the *A. fumigatus* series. (A) Single nucleotide polymorphism based phylogenetic tree was constructed using the SNPhylo pipeline and the whole genome sequences of the entire series as well as unrelated isolates IFM59361-1, 09-7500806, 08-19-02-61 and Afu 1042/09. (B) Unrooted phylogenetic tree of the series constructed using the SNPhylo pipeline. Tree scale represents nucleotide substitutions per site.

A total of 248 non-synonymous SNPs, absent in early isolates V130-15 and V130-14, were identified in later isolates ([Table A.2](#t0020){ref-type="table"}). These SNPs are predicted to have developed during the course of infection and in-host microevolution of the precursor strain (V130-15). SNPs of particular interest were identified based on their occurrence in multiple isolates or being localised in genes encoding proteins considered to play an important role in fungal cell metabolism and growth ([Table 2](#t0010){ref-type="table"}). The genes identified were located across all 8 chromosomes and encoded a range of proteins including phospholipases (AFUA_3G07940 phosphoinositide phospholipase C), protein kinases (AFUA_2G01700 Snf1) and cell division control proteins (AFUA_3G10250 Cdc15). Cyp51A SNPs were identified in 9 isolates in the series. V157-39 harboured G54R; V157-40 harboured G54V; isolates V157-47, V157-48 and V157-80 harboured P216L; isolates V157-59, V157-60, V157-62 and V157-61 harboured M220R. SNPs were also identified in a range of uncharacterised proteins. For example, V204A SNP in AFUA_4G08100 was demonstrated in isolates V157-39, V157-48, V157-59, V157-60, V157-62, V157-61 and V157-80. A wide range of Cyp51A SNPs were identified, supporting the prediction that the isolates took on independent lineages of microevolution ([Fig. 2](#f0010){ref-type="fig"}B).Table 2Non synonymous single nucleotide polymorphisms of particular interest present in isolates within the series.GeneDescriptionV130-18V130-54V157-39V157-40V157-47V157-48V157-59V157-60V157-62V157-61V157-80AFUA_1G09270Transmembrane glycoproteinS772NS772NS772NS772NS772NS772NAFUA_1G12540TMEM1 family proteinF879CF879CF879CF879CAFUA_2G01700Carbon catabolite Derepressing protein kinase Snf1R188QR188QR188QR188QAFUA_2G02320Hsp70 chaperone (BiP)490^\*^490^\*^AFUA_2G08040C6 finger domain proteinD347YD347YD347YD347YD347YD347YD347YAFUA_3G07940Phosphoinositide phospholipase CKSS213KSKSS213KSKSS213KSKSS213KSAFUA_3G08990Cell surface proteinF141SF141SAFUA_3G10250Cell division control protein (Cdc15)D220GD220GD220GD220GD220GD220GD220GD220GAFUA_3G11940Chromatin modification-related protein154X292^\*^292^\*^292^\*^292^\*^154XAFUA_4G06890Cyp51AG54RG54VP216LP216LM220RM220RM220RM220RP216LAFUA_4G08100Uncharacterised proteinV204AV204AV204AV204AV204AV204AV204AAFUA_4G13800Exo-alpha-sialidaseT214KT214KT214KT214KAFUA_4G14310Uncharacterised proteinA207I V209IA207I V209IA207I V209IA207I V209IA207I V209IAFUA_5G03760Endochitinase A1S438PS438P V436IAFUA_5G04050Scramblase family protein128^\*^128^\*^128^\*^128^\*^128^\*^128^\*^AFUA_6G00530Uncharacterised proteinY380HY380HY380HY380HY380HY380HAFUA_6G10050Small oligopeptide transporter, OPT familyG428SG428SG428SG428SG428SG428SG428SG428SAFUA_6G10620Nuclear pore complex subunitD43ND43ND43ND43ND43ND43ND43ND43NAFUA_6G14720Telomere-associated RecQ helicaseI1077VI1077V P1152L R984CG1119RR984C A994V S996ND123NT969A[^2]

Of the SNPs identified, of particular interest was F125L in ZrfC alkaline zinc transporter (AFUA_4G09560) in the last isolate of the series, V157-80. F125L lies in the highly conserved ETFCND motif, which is C-terminal of a zinc-binding motif ([@b0225]). The strict conservation of this motif indicates importance ([@b0225]). Zinc depletion assays were performed in order to assess whether this isolate possessed any growth differences as a result of this SNP in zinc-limiting environments, much like the human host.

Isolate V157-40 was selected as a control strain with a similar genetic background; both V157-40 and V157-80 possessed MICs \> 16 mg/L for both ITR and POS. There were no significant growth differences between isolates V157-40 and V157-80 in the presence and absence of 1 mM zinc at pH 4.5 and 7.5. Both isolates exhibited significantly enhanced colony growth in the absence of zinc at pH 7.5 in comparison to pH 4.5 (p \< 0.05). In the presence of zinc, growth differences between pH 4.5 and 7.5 were negligible in both isolates ([Fig. 3](#f0015){ref-type="fig"}). In summary, the SNP observed in ZrfC does not appear affect the ability to scavenge zinc under the conditions tested.Fig. 3Comparison of mycelial growth of *A. fumigatus* isolates V157-40 and V157-80 in the presence and absence of zinc at pH 4.5 and 7.5. Isolates were pre-cultured on glucose minimal media lacking zinc for 7 d at 37 °C. Conidia were harvested via immersion in 30 mL PBS containing 0.05% Tween-80 and counted. Glucose minimal media plates lacking zinc or containing 1 mM zinc at pH 4.5 and 7.5 were spot inoculated with 5 × 10^2^ conidia. Every 24 h for 96 h colony diameter was measured; results at 96 h are shown. Data was obtained in triplicate and mean values ± SD are shown (^\*^p \< 0.05; two-tailed Students T-test).

### 3.2.2. Phenotypic analysis {#s0105}

The isolates showed variations in their growth kinetics in control liquid and solid media. The mean OD~450~ after 48 h growth in liquid media ranged from 0.666 (V130-18) to 0.818 (V157-48) (p = NS). All isolates cultured on solid media for 96 h showed growth colony diameters of between 30.2 (V130-14) and 37.5 mm (V157-39) (p = NS). Isolate V157-62 was an exception to this range. This isolate possessed a significantly decreased mean 96 h colony diameter of 16.2 mm (p = 0.003 compared to the mean of isolates V130-15, V157-39, V157-47 and V157-59). This represents a mycelial growth rate 52% slower than the other isolates ([Fig. 1](#f0005){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}). Specific isolates (V130-15, V157-39, V157-47, V157-62 and V157-59) were selected for detailed phenotypic analyses to assess their response to antifungal stressors. These isolates were considered representative of the different azole resistance profiles, Cyp51A mutations and growth rates observed in the series. As shown in [Table 1, V130-15](#t0005){ref-type="table"} was azole susceptible without Cyp51A SNPs; V157-39 harboured G54R in Cyp51A and was ITR and POS resistant; V157-47 harboured P216L in Cyp51A and was ITR and POS resistant; V157-62 had a growth defect, harboured M220R in Cyp51A and was ITR, VORI and POS resistant; V157-59 harboured M220R in Cyp51A and was ITR, VORI and POS resistant. As anticipated, in both solid and liquid media, isolates were unable to grow in the presence of a mould-active azole at a concentration higher than its MIC. Resistant isolates exhibited a concentration dependent decrease in growth in the presence of azole antifungal agents in both solid and liquid media ([Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}). None of the isolates exhibited enhanced growth in comparison to control conditions in the presence of azole antifungals.Fig. 4Comparison of mycelial growth of selected *A. fumigatus* isolates on solid media with increasing concentrations of itraconazole. Sabouraud dextrose agar plates were spot inoculated with 5 × 10^2^ conidia and incubated at 37 °C. Colony diameter was measured every 24 h for 96 h; results for 96 h are shown. Data was obtained in triplicate and mean values ± SD are shown (^\*^p = 0.003 compared to mean of V130-15, V157-39, V157-47 and V157-59; two-tailed Students T-test).Fig. 5Growth kinetics of selected *A. fumigatus* isolates in liquid media. Flat-bottomed 96-well plates were seeded with 1 × 10^5^ conidia in RPMI with or without voriconazole (A) or posaconazole (B) in various concentrations. Plates were incubated at 37 °C for 48 h inside a spectrophotometric plate reader; the optical density at 450 nm was automatically measured every 20 min with 5 s shaking before every reading. Optical density at 48 h is shown. Data was obtained in duplicate, mean values ± SD are shown. No significant differences were observed between isolates under the same condition.

The series of strains were isolated from a CGD patient. This group of patients possess a defect in the nicotinamide adenine dinucleotide phosphate (NAPDH) oxidase complex, this results in a failure to mount a phagocyte respiratory burst and produce superoxide ([@b0200]). In order to assess whether the isolates displayed enhanced sensitivity to oxidative stress, as a result of adaptation in the CGD host, growth in the presence of *t*BOOH was assessed in both liquid and on solid media. Growth of all 5 isolates was fully inhibited by the presence of 2.5 mM tBOOH (data not shown). All 5 isolates grew normally at lower concentrations, indicating normal sensitivity to oxidative stress ([@b0110]).

In order to further investigate the growth and development of the isolates, conidiation levels were quantified ([Fig. 6](#f0030){ref-type="fig"}). Under control conditions, specific resistant isolates (V157-39, V157-40, V157-47, V157-48, V157-62, V157-59, V157-60, V157-61, and V157-80) produced on average 5-fold less conidia than earlier isolates (V130-15, V130-14, V157-18 and V157-54) (p = 0.038). Conidia production in ITR resistant isolates (V157-39, V157-40, V157-47, V157-62, V157-60 and V157-80) increased on average 7-fold in the presence of 4 mg/L ITR (p = 0.041). Isolates V157-39 and V157-62 produced 5-fold (p = 0.023) and 3-fold (p = 0.0009) more conidia respectively in the presence of 4 mg/L ITR than susceptible isolates under control conditions. In summary, the majority of resistant isolates displayed increased levels of conidiation in the presence of 4 mg/L ITR. Isolates V157-48, V157-59 and V157-61 did not display this trend. However, upon passaging sterile hyphae onto 4 mg/L ITR, enhanced sporulation was observed.Fig. 6Comparison of amount of conidia produced by the *A. fumigatus* strains throughout the series. T75 culture flasks containing Sabouraud dextrose agar with or without the addition of 4 mg/L itraconazole, were inoculated with 1x10^5^ conidia and incubated at 37 °C for 7 d. Conidial suspensions were prepared *via* immersion in 30 mL PBS containing 0.05% Tween-80 and counted. Data was obtained in duplicate and mean values ± SD are shown (^\*^p = 0.023, ^\*\*^p = 0.0009; two-tailed Students T-test).

### 3.2.3. Differences in virulence between isolates {#s0110}

In order to assess associated changes in virulence in the series, survival studies were performed using the well-established invertebrate model of systemic infection, *Galleria mellonella* ([@b0165], [@b0295], [@b0320]). Clear differences in mortality rates were observed for the isolates tested ([Fig. 7](#f0035){ref-type="fig"}). The percentage survival at 6 d ranged from 10% (isolate V157-39) to 60% (isolate V157-62). The percentage survival at 6 d was 40% after infection with the first isolate (V130-15). Survival after infection with isolate V157-62, the only isolate with a growth defect, was significantly higher than after infection with isolate V130-15 (p = 0.037). Survival after infection with isolate V157-39 was significantly lower than after infection with isolate V130-15 (p = 0.01). No associations between virulence and conditions levels and/or resistance profile could be made.Fig. 7Survival of *Galleria mellonella* larvae infected with specific isolates. Groups of 10 *G. mellonella* larvae were infected with 6 × 10^3^ conidia in the last pro-leg using a 0.33 mm Micro-Fine needle. Two control groups of larvae were included in each experiment; 10 unmanipulated larvae and 10 larvae injected with phosphate-buffered saline. Larvae were monitored for 6 d; larval death was characterised by lack of movement and melanisation. Survival after infection with isolate V157-62 or V135-39 was significantly higher in comparison to isolate V130-15 (^\*^p \< 0.05; two-tailed Students T-test).

4. Discussion {#s0115}
=============

In this study we investigated the dynamics of both physiological and genetic adaptation in *A. fumigatus* throughout chronic and recurrent infection. Central to this study was our series of 13 isolates obtained from a single chronic granulomatous disease patient over a period of 2 years. Using this unique series, we identified large numbers of genetic changes thought to have occurred throughout infection and disease. These non-synonymous mutations identified have potential to play a role in adaptation to the human host under antifungal therapy. Additionally, we identified one isolate that displays a severe growth defect. We also observed significant differences in the ability of the isolates to produce conidia. Isolates were demonstrated to exhibit varying levels of virulence and be more equipped to cope with zinc depletion at pH 7.5 in comparison to pH 4.5, which is consistent with previous findings ([@b0015]).

It is hypothesised that advantageous SNPs, which have developed during natural random mutation, are selected for during exposure to in-host stressors, such as azoles and effectors of the innate immunity. Subsequent natural selection is thought to enable survival. Here, we identified 248 SNPs predicted to have arisen during the course of infection in one host. Specific proteins were mutated in multiple isolates in the series. The identified proteins are involved in a wide range of cellular activities, indicating the stressors present in-host to be equally wide ranging. It is expected that the identified proteins play a role in in-host adaptation. Azole target Cyp51A is a hotspot for mutations conferring azole resistance ([@b0380]). Nine isolates within our series contained a SNP in Cyp51A. As the initial susceptible isolates lacked Cyp51A SNPs it can be concluded that these SNPs developed in-host, presumably as a result of azole pressure. Isolates contained either G54R, G54V, P216L or M220R SNPs, all of which have previously been proven to result in azole resistance to varying degrees ([@b0045], [@b0070], [@b0085], [@b0140], [@b0175], [@b0180], [@b0205], [@b0230], [@b0235], [@b0245], [@b0240], [@b0330], [@b0375]). In most cases the Cyp51A SNP present did not fully explain the resistance profile observed, indicating the presence of additional non-*cyp51A* mediated resistance mechanisms. As an example, isolate V157-39 was highly resistant to both POS and ITR. This isolate possessed a G54R substitution in Cyp51A, which has previously been shown to confer ITR resistance ([@b0235]). The POS resistance of this isolate is as yet unexplained.

Four isolates possessed SNP R188Q in Snf1 kinase; this protein is known to be involved in nutrient limitation and salt stress responses in *Saccharomyces cerevisiae* ([@b0190], [@b0300]). It is possible that R188Q alters Snf1 functionality, potentially enhancing the ability of the isolates to cope with these stresses, which could enable persistence of infection. Furthermore, 7 isolates possessed SNP D347Y in C6 finger domain protein (AFUA_2G08040). This protein possesses RNA polymerase II transcription factor activity and is zinc ion binding ([@b0040]). Interestingly, Hagiwara *et al* also reported a mutation (Y958) in this C6 finger domain protein, predicted to have developed throughout infection in an invasive pulmonary aspergillosis patient ([@b0170]). This supports our hypothesis that the identified proteins are involved in in-host adaptation.

Fitness losses in clinical azole resistant *A. fumigatus* isolates are frequently reported ([@b0170], [@b0355]). Various methods of assessing fitness are described in *A. fumigatus* ([@b0030], [@b0210], [@b0355])*.* In this study we performed liquid and solid media growth assays. These growth assays were selected to represent different forms of *in vivo* growth. Liquid assays were deemed a basic representation of growth in human tissue, where conidiation does not occur. Solid media assays were chosen to crudely represent growth with sporulation, which occurs when the fungus is in contact with the air, as on the epithelial lining of the airways. Isolate V157-62 was shown to harbour defects in both conidiation and growth on solid media. This isolate contains a M220R Cyp51A mutation. Previous *in vivo* competition studies, using both immunocompetent and immunosuppressed mice, have shown that M220 SNPs are not associated with fitness costs ([@b0210], [@b0355]). It is possible that other SNPs gained as a result of adaptation are the cause of this fitness defect. These SNPs could be either beneficial and associated with a fitness cost or simply disadvantageous. Clues can be obtained using whole genome sequencing however further research is required to definitively associate specific SNPs, or combinations thereof, with this phenotype.

Later isolates were shown to produce significantly fewer conidia than earlier more susceptible isolates. Conidiation in specific isolates was restored in the presence of itraconazole. This could be classified as azole addiction, where the fungus has adapted to grow in the presence of azole and as a result requires it for specific aspects of growth. These isolates do not share an isolation date or resistance profile, but perhaps shared localisation within the lung and therefore adapted similarly. As the majority of isolates possessed normal mycelial growth rates, the defect lies directly in the isolates' ability to form conidia. In agreement with our findings, Hagiwara et al also reported a sporulation defect in serially isolated clinical strains from individual patients ([@b0170]). It can be hypothesised that the virulence of the poorly sporulating isolates is unaffected by this defect as conidiation is rarely observed in human tissue and is not required for invasive disease pathogenesis. However, the environmental spread of resistant isolates with this defect is likely to be limited.

Interestingly, under zinc depletion isolates grew better at pH 7.5 in comparison to pH 4.5. ZrfC is central to this behaviour. This zinc transporter is capable of functioning under alkaline zinc limiting conditions due to its N-terminus, which is also predicted to scavenge Zn^2+^ from host tissues ([@b0020], [@b0370]). It is probable that these strains have evolved in host and are therefore more adapted to scavenge zinc and thrive at physiological pH in host. Survival in acidic conditions is perhaps driven by adaptation to the ecological niche of *A. fumigatus* in soil. The SNP identified by us in the ZrfC in V157-80 did not influence the capability to grow in alkaline zinc limiting conditions and seems not to play a role in in-host adaptation.

The phenotypic and genotypic changes observed in the series may be associated with the virulence differences observed in our experimental *G. mellonella* model. Isolates exhibited both increased and decreased virulence in comparison to the precursor isolate (V130-15). The isolate determined to have a growth defect *in vitro* (V157-62) showed attenuated virulence in comparison to V130-15. This could be a direct impact of its slower mycelial growth. Another azole resistant isolate (V157-39) showed enhanced virulence in comparison to V130-15. In agreement with previous findings, no associations could be made between resistance development and changes in virulence ([@b0210], [@b0355]). Furthermore, no associations could be made between conidiation levels and virulence. As mycelial growth drives invasion in-host rather than conidiation, it is possible that differences in conidiation ability have minimal impact on ability to cause infection. It is likely that microevolution has driven both increases and decreases in virulence. Attenuated virulence may well be a cost associated with another yet unidentified adaptation mechanism. Increases in virulence are regarded as direct adaptation to enable persistence.

5. Conclusions {#s0120}
==============

In summary, *A. fumigatus* undergoes substantial in-host adaptation. This adaptation occurs on both a physiological and genetic level as illustrated by our results, and is hypothesised to enable persistence of infection in some cases. Genetic changes reported here are wide ranging, suggesting that the stressors driving adaptation are equally wide ranging. It should be noted that as this study involves a series of isolates from a single chronic granulomatous disease patient, adaptation dynamics reported may not be representative of other patient groups and/or other patients with chronic granulomatous disease. However, this study is the first to provide in depth analysis into the genetic and physiological changes that occur in *A. fumigatus* during adaptation to the human host.

Appendix A {#s0130}
==========

[Table A.1](#t0015){ref-type="table"}Table A1Mean coverage and mapping quality of whole genome sequence data sets to Af293 reference.StrainMean coverage (X)Mean mapping qualityV130-156940V130-148539V130-1811839V130-546939V157-396240V157-407641V157-472037V157-482537V157-625341V157-597740V157-605841V157-616139V157-807141  Mean across series6540

[Table A.2](#t0020){ref-type="table"}Table A2Non synonymous single nucleotide polymorphisms identified to have developed throughout the course of infection in the series of isolates.GeneDescriptionV130-18V130-54V157-39V157-40V157-47V157-48V157-59V157-60V157-62V157-61V157-80AFUA_1G00220Uncharacterised proteinA430V T437I 348 S493LAFUA_1G00230Uncharacterised protein748^\*^L756A748^\*^AFUA_1G00550Uncharacterised proteinA430VT11MV369LS168L M170I V173I D175N R176C T182C T182IAFUA_1G00750Uncharacterised protein171 A170T M162I P155L M153I S152LAFUA_1G12130Translation initiation factor eIF4EV160AAFUA_1G06060Uncharacterised proteinA786T G608V S772NAFUA_1G08920IQ calmodulin-binding motif domain proteinA189VAFUA_1G09270Transmembrane glycoproteinS772NS772NS772NS772NS772NS772NAFUA_1G12540TMEM1 family proteinF879CF879CF879CF879CAFUA_1G15940Auxin Efflux Carrier superfamilyG318GGGSG281CAFUA_2G00230Amid-like NADH oxidoreductaseE240AAFUA_2G01700Carbon catabolite derepressing protein kinase Snf1R188QR188QR188QR188QAFUA_2G02320Hsp70 chaperone (BiP)490^\*^490^\*^AFUA_2G04290Cytochrome P450 monooxygenaseN176SAFUA_2G07450PX domain proteinL282FAFUA_2G08040C6 finger domain proteinD347YD347YD347YD347YD347YD347YD347YAFUA_2G09710Protein kinase (NpkA)P414LAFUA_2G11570F-box domain proteinG204VAFUA_2G12360WD repeat proteinE942KAFUA_2G13500Uncharacterised proteinTAFUA_2G13770C2H2 conidiation transcription factor FlbC218^\*^AFUA_2G16170DNA-directed RNA polymerase III RPC4R16AAFUA_2G13960TafazzinL157FAFUA_2G16830Endonuclease/exonuclease/phosphatase family proteinG190RAFUA_2G17000PT repeat family proteinE1362KAFUA_2G17600Conidial pigment polyketide synthase PksP/Alb1S1197YAFUA_2G18100Telomere-associated RecQ helicaseAFUA_3G02550Uncharacterised proteinY33F S34LAFUA_3G02640Nucleoside-diphosphate-sugar epimerase family protein237 A243T T248CAFUA_3G03852C2H2 type zinc finger domain proteinC292YAFUA_3G04300Actin cytoskeleton organization and biogenesis proteinP1125HAFUA_3G07080UPF0016 domain proteinV470MAFUA_3G07940Phosphoinositide phospholipase CKSS213KSKSS213KSKSS213KSKSS213KSAFUA_3G08570Uncharacterised proteinV54LAFUA_3G08990Cell surface proteinF141SF141SAFUA_3G10250Cell division control protein (Cdc15)D220GD220GD220GD220GD220GD220GD220GD220GAFUA_3G10290Uncharacterised proteinR198WAFUA_3G10450Uncharacterised proteinR718CAFUA_3G11940Chromatin modification-related protein154X292^\*^292^\*^292^\*^292^\*^154XAFUA_3G14445Bromodomain associated domain proteinR223CAFUA_3G14510Rhamnogalacturonan acetylesterase RgaEP186LAFUA_3G14700Polyketide synthaseA1923GAFUA_4G04760Inositol kinase kinase (UvsB)E485QAFUA_4G06890Cyp51AG54RG54VP216LP216LM220RM220RM220RM220RP216LAFUA_4G07530Uncharacterised protein288HDDAFUA_4G08100Uncharacterised proteinV204AV204AV204AV204AV204AV204AV204AAFUA_4G08360Mediator of RNA polymerase II transcription subunit 8E188VAFUA_4G09560ZIP Zinc transporterF125LAFUA_4G12050Thermoresistant gluconokinase family proteinL196VAFUA_5G12440Cell cycle control protein (Cwf23)A242VAFUA_4G13000Lysine-specific histone demethylase Aof2E2DAFUA_4G13800Exo-alpha-sialidaseT214KT214KT214KT214KAFUA_4G14310Uncharacterised proteinA207I V209IA207I V209IA207I V209IA207I V209IA207I V209IAFUA_5G02390Auxin Efflux Carrier superfamilyV403DAFUA_5G03760Endochitinase A1S438PS438P V436IAFUA_5G04050Scramblase family protein128^\*^128^\*^128^\*^128^\*^128^\*^128^\*^AFUA_5G07140Translation elongation factor G2A542SAFUA_5G08330RNA binding proteinT209SAFUA_5G08390Response regulatorV706FAFUA_5G11820Survival factor 1213^\*^AFUA_5G14920Uncharacterised proteinW372SAFUA_5G14865Uncharacterised protein301^\*^AFUA_6G00530Uncharacterised proteinY380HY380HY380HY380HY380HY380HAFUA_6G04080Uncharacterised proteinA1393TAFUA_6G05280Meiosis protein MEI2K417NAFUA_6G06335Histone-lysine N-methyltransferase, H3 lysine-4 specificR578CAFUA_6G07660Uncharacterised proteinE169KAFUA_6G10050Small oligopeptide transporter, OPT familyG428SG428SG428SG428SG428SG428SG428SG428SAFUA_6G10380Cullin binding protein CanAL91VAFUA_6G10490Uncharacterised proteinY365CAFUA_6G10620Nuclear pore complex subunitD43ND43ND43ND43ND43ND43ND43ND43NAFUA_6G12950Alpha, alpha-trehalose-phosphate synthase (UDP-forming)V265AAFUA_6G13660Uncharacterised proteinP865LAFUA_6G13800Integral membrane protein Pth11-likeW148CAFUA_6G13900Uncharacterised proteinK413NAFUA_6G14720Telomere-associated RecQ helicaseI1077VI1077V P1152L R984CG1119RR984C A994V S996ND123NT969AAFUA_7G00720Uncharacterised proteinA311TA311TA311TAFUA_7G01290Uncharacterised proteinG51RAFUA_7G01310C6 transcription factorQ538HAFUA_7G01960Uncharacterised protein167^\*^AFUA_7G04180Amine oxidaseR614PAFUA_7G05220Mitochondrial carrier proteinV639LAFUA_7G05960C2H2 finger domain proteinG792DAFUA_7G08250C6 finger domain proteinS749GS749GAFUA_7G08630Uncharacterised proteinAFUA_8G00750C2H2 transcription factorQ429KC45YAFUA_8G01820Uncharacterised proteinGXAFUA_8G02420Uncharacterised proteinEAFUA_8G02850Actin binding proteinS505TAFUA_8G04520Cytoskeleton assembly control protein Sla1Q257KAFUA_8G05780NACHT and Ankyrin domain proteinK618E Q622HAFUA_8G06132FluG domain proteinG81R M90I A135I E142K R79H T82MA135IAFUA_8G06140Sensor histidine kinase/response regulatorA231I F232L M222D S223N T218AAFUA_8G06210Metalloreductase transmembrane componentR479YAFUA_8G06220Uncharacterised proteinS238L V245IS238L 239 V245I 249 V249M G252S 253AFUA_8G06230Uncharacterised proteinV50M[^3]
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For interpretation of color in Fig. 1, the reader is referred to the web version of this article.

[^1]: Bold indicates a MIC exceeding the EUCAST clinical resistance breakpoint; which are defined as itraconazole \>2 mg/L, voriconazole \>2 mg/L and posaconazole \>0.25 mg/L.

[^2]: Isolates V130-15 and V130-14 have been excluded from this table as they were defined as references, and therefore did not contain any substitutions.

[^3]: Isolates V130-15 and V130-14 have been excluded from this table as they were defined as references, and therefore did not contain any substitutions.
